Investors
Board and leadership
Key to committees/roles:
- E Executive
- N Nomination
- A Audit and Risk
- R Remuneration
- Chair
Mark Capone, MSc
Non-Executive Director
Appointment: 28 January 2021
- R
Background: Based in the US, Mark Capone is an accomplished life sciences executive. He spent over 17 years with Myriad Genetics, latterly as CEO and President, over which time he grew the company into a leading global precision medicine company. Prior to this Mark spent 17 years with Eli Lilly and Company in positions across the entire value chain. Mark is currently CEO of Precision Medicine Advisors, a consultancy for molecular diagnostics, pharmaceuticals, and biotechnology organizations, which he founded in 2020, and a non-executive of Nephrosant, a private US company focused on developing diagnostic tools for Chronic kidney Disease, and Microba, a precision microbiome science company.
Current external appointments: Mark is currently CEO of Precision Medicine Advisors and a non-executive director of Nephrosant and Microba.
Skills, experience and contribution: Mark has significant Life Science industry experience and of working in companies of different scale. He is an accomplished healthcare CEO with experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. He has extensive US public and private board experience across a large range of companies specializing in growth.
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
abcam.comabcam.co.jp
abcam.cn
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds. Static content was last updated on 09 Nov 2020.
Website by FisherPaul
